CAPS Capstone Holding Corp.
Basic MaterialsAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.31
P/S
0.04
EV/EBITDA
-7.01
DCF Value
$-11.39
FCF Yield
-256.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
24.1%
Operating Margin
-7.1%
Net Margin
-42.9%
ROE
-114.8%
ROA
-41.1%
ROIC
-9.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $12.6M | $-1.9M | $— |
| Q4 null | $12.5M | $-17.5M | $— |
| FY null | $46.9M | $-21.2M | $— |
| Q3 null | $13.7M | $-2.0M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Basic Materials
Industry
Construction Materials
Country
US
Exchange
—
Beta
-1.59
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.